MSC Therapy for Systemic Sclerosis: iPSC-Derived Stem Cells, Clinical Trials, and the Vasculopathy-Fibrosis Mechanism

A comprehensive 2026 review of mesenchymal stem cell therapy for systemic sclerosis (scleroderma), covering iPSC-derived MSCs, refrigerated cell delivery, blood vessel organoid models, and the MANUS clinical trial for digital ulcers.

Lire la suite...

MSC Therapy for Ischemic Stroke: What a 2026 Umbrella Review and Network Meta-Analysis of 1,006 Patients Reveal

The 2026 evidence base for mesenchymal stem cell therapy in ischemic stroke includes a 26-study umbrella review and an 18-RCT network meta-analysis of 1,006 patients. MSCs were the only cell type to significantly reduce mortality. This medical review synthesizes the latest clinical data, mechanisms, active trials, and translational barriers.

Lire la suite...

MSC Therapy for Multiple Sclerosis: What 17 Trials and Tell Us

MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.

Lire la suite...

MSC Therapy for Burn Wounds and Chronic Skin Regeneration: 2026 Breakthroughs in Exosome-Based Healing

New 2026 research reveals UC-MSC exosomes combined with low-intensity pulsed ultrasound and curcumin-hydrogel systems achieve remarkable burn wound healing — including MRSA-infected wounds — through autophagy regulation, anti-scarring mechanisms, and immunomodulation. Five landmark papers reviewed.

Lire la suite...
Haut